TP53 and outcome in DLBCL: not only the coding region.

TP53 and outcome in DLBCL: not only the coding region.

Blood (2013-06-01)

Fabrice Jardin, Bertrand Coiffier

ABSTRACT

In this issue of Blood, Li et al report mutations in the 3′ untranslated region (3′UTR) of TP53 that modify the expression of p53 and thus its effect on response to therapy in diffuse large B-cell lymphoma (DLBCL) patients.

MATERIALS

Product Number

Brand

Product Description

C7397

Sigma-Aldrich

Cyclophosphamide monohydrate, ISOPAC^®

V8879

Sigma-Aldrich

Vincristine sulfate salt, 95.0-105.0% (HPLC), powder or crystals

C0768

Sigma-Aldrich

Cyclophosphamide monohydrate, bulk package

PHR1042

Supelco

Prednisone, Pharmaceutical Secondary Standard; Certified Reference Material

D2975000

Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard

44583

Sigma-Aldrich

Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)

V8388

Sigma-Aldrich

Vincristine sulfate, meets USP testing specifications

V0400000

Vincristine sulfate, European Pharmacopoeia (EP) Reference Standard

D1515

Sigma-Aldrich

Doxorubicin hydrochloride, 98.0-102.0% (HPLC)

P6254

Sigma-Aldrich

Prednisone, ≥98%